The sodium-glucose cotransporter-2 (SGLT2) inhibitors empagliflozin and dapagliflozin reduce cardiovascular death and heart failure hospitalizations in patients with heart failure.1 However, cardiac medications within the same class may not all have the same benefit. Here, SLC5A2 is linked to heart failure.